Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
May 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
Jan 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia |
Jun 2023 |
Blood |
Aplastic Anemia |
Newly revised 2023 MDS response criteria |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
Jul 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
Sep 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |